Neurocode Launches Groundbreaking pTau217 Blood Test for Alzheimer's Disease Clinical Diagnosis

Neurocode USA, Inc. has launched ALZpath Dx, an innovative blood test for Alzheimer’s disease (AD) that measures circulating levels of pTau217. This test is the first of its kind available for clinical diagnostic use in the U.S., offering accuracy comparable to brain imaging or CSF testing but with greater accessibility, lower cost, and less invasiveness. The ALZpath Dx test, powered by Quanterix Simoa technology, marks a significant advancement in early and accurate AD diagnosis, patient stratification for clinical trials, and treatment monitoring.